. 2018 Nov 28;6(2):109–127. doi: 10.1007/s40487-018-0089-z

Table 2.

IL-1 inhibitors and their corresponding clinical trials

Name	Company	Target molecular mechanism	Cancer indication	Most advanced phase	Publication	Status	Trial number
Other/previous names	Company	Target molecular mechanism	Cancer indication	Most advanced phase	Publication	Status	Trial number
Xilonix	Xbiotech	IL-1α	Pancreatic cancer with cachexia	Phase I		Recruiting	NCT03207724
Xilonix		IL-1α	Advanced cancers NSCLC (subgroup)	Phase I	Hong et al. 2014 [92] Hong et al. 2015 [93]	Completed	NCT01021072
MABp1, CV-18C3, T2-18C3, RA-18C3, CA-18C3, bermekimab, hutruo		IgG1 True Human mAb	Advanced cancers NSCLC (subgroup)	Phase I	Hong et al. 2014 [92] Hong et al. 2015 [93]	Completed	NCT01021072
			CRC	Phase III Phase III	Hickish et al. 2017 [95] Fisher 2015 [94]	Completed Completed	NCT02138422 NCT01767857
			Hematologic malignancies	Phase I		Completed	NCT01260545
Canakinumab	Novartis	IL-1β	NSCLC	Phase III Phase III Phase III		Not yet recruiting Not yet recruiting Recruiting	NCT03631199 NCT03626545 NCT03447769
Canakinumab		IL-1β	Melanoma	Phase II		Not yet recruiting	NCT03484923
Ilaris, ACZ885		Human IgG1/k mAb	CRC, TNBC, NSCLC—adenocarcinoma	Phase IB		Recruiting	NCT02900664
Ilaris, ACZ885		Human IgG1/k mAb	Atherosclerosis → lung cancer		Ridker et al. 2017 [98]	Active, not recruiting	NCT01327846
P2D7KK	A*STAR	IL-1β mAb	Multiple myeloma		Goh et al. 2014 [99]	Preclinical phase
Anakinra	Swedish Orphan Biovitrum AB	A recombinant, nonglycosylated Il-1Ra	Multiple myeloma	Phase II Phase II		Recruiting	NCT03233776
			Multiple myeloma	Phase II Phase II	Lust et al. 2016 [102] Lust et al. 2009 [101]	Completed	NCT00635154
			Early multiple myeloma	Phase I/II		Suspended (09/2018)	NCT02492750
			Pancreatic cancer	Phase I Phase I		Recruiting Active, not recruiting	NCT02550327 NCT02021422
			Metastatic colorectal cancer	Phase II		Completed	NCT02090101
Kineret			Metastatic colorectal cancer	Phase II		Completed	NCT02090101
			Metastatic breast cancer	Phase I		Unknown	NCT01802970
			Advanced cancers	Phase I		Active, not recruiting	NCT01624766
			Metastatic adult solid tumors	Phase I		Completed	NCT00072111
IP-1510	Itis Pharmaceuticals	A synthetic IL-1Ra	Cancer-related cachexia	Phase I/II	Paspaliaris et al. 2011 [103]
IP-1510D	Itis Pharmaceuticals	A synthetic IL-1Ra	Cancer-related cachexia	Phase I/II	Paspaliaris et al. 2011 [103]
Nidanilimab	Cantargia	IL-1RAP	NSCLC, PDAC, TNBC, CRC	Combined phase I/IIA		Recruiting	NCT03267316
Can-04	Cantargia	IgG1 True Human and ADCC enhanced mAb	Leukemia	Preclinical development
CSC012-ADC	Cellerant Therapeutics	IL-1RAP	Acute myeloid leukemia	Preclinical development
CLT012	Cellerant Therapeutics	Ab–drug conjugate	Acute myeloid leukemia	Preclinical development

mAb monoclonal antibody, NSCLC non-small cell lung cancer, CRC colorectal cancer, TNBC triple-negative breast cancer, PDAC pancreatic ductal adenocarcinoma